Objectives: Congenital heart defect (CHD) is the one of the major causes for neonatal lethality. And ultrasound screening enables the early diagnosis of CHD in prenatal stage. Emerging studies by using chromosomal microarray analysis of prenatal samples show that pathogenic copy number variants (CNVs) are highly associated with CHD. Methods: Here, we collected DNA samples from 145 unrelated fetuses with CHD diagnosed by ultrasound screening and subjected them for CNV analysis by low-pass whole-genome sequencing. CNV classification was performed according to the guideline from the American College of Medical Genetics. Maternal ages are 27.6±3.73, while the gestational weeks are 24.4±5.2. Sixty-one samples out of them are intra-cardiac defects (42.1%) and the remaining samples are extra-cardiac abnormalities (57.9%).Subtype classification of two groups is different, in intracardiac defect, the top were TOF (21.3%), TGA(14.8%) and AVSD (11.8%), while, the other were VSD (21.4%), AVSD (16.7%) and PS (13.1%). Results: Aneuploidies were identified in 29 (20%) fetuses, 27 out of them were with extra-cardiac abnormalities. Pathogenic CNVs were detected in seven cases, including a heterozygous loss at 22q13 harbouring FBLN1 and a gain at 10q23.31q26.3 with SHOC2 and ANKRD1.There were 344 unknown clinical significance micro-duplication or micro-deletion found in 91 samples, the number of CNV per sample was more in extra-cardiac abnormalities group when compared to intra-cardiac defect (p-value = 0.1514). 7.53% of which were predicted to be pathogenic by DECIPHER and GeneReviews. Conclusions: Our study demonstrates the potential clinical diagnostic utility of genomic imbalance profiling in CHD patients.
Objectives: It is expected that many pregnant women will choose for NIPT instead of first trimester combined testing (ftCT). As a consequence high risk pregnancies may be identified later on in the pregnancy. NIPT performed in high risk pregnancies may lead to a diagnostic delay of some chromosome aberrations. The aim of this study was to evaluate the risk of a diagnostic delay in our cohort of high risk pregnancies tested with NIPT. Methods: 2014-2015 NIPT was performed in 1071 high risk pregnancies (risk > 1:200 after ftCT). 39 (3.6%) women subsequently chose array testing due to further doubts (10), an ultrasound anomaly found later on in the pregnancy (21) or fetal death (IUFD, 8) . Results: In 3 fetuses a pathogenic fetal unbalanced chromosome aberration matching the indication was found (isochromosome Xq, a de novo atypical 22q11 microdeletion and triploidy). Thus, in ca. 1:350 (3/1071) ''false'' reassurance was given with normal NIPT results and a diagnostic delay to the second trimester occurred. This is an underestimation of the overall diagnostic delay since not all unbalanced chromosome aberrations manifest ultrasound anomalies or cause IUFD. Besides this, developmental delay and intellectual disability are not immediately evident at birth. Conclusions: As the detection of severe chromosome disorders is more traumatic when discovered late in pregnancy and both the medical as well as psychological impact of a pregnancy termination are more severe, it is important to avoid diagnostic delay. Thus, it is of importance to identify high risk pregnancies either through searching for (new) early ultrasound markers or to offer higher resolution NIPT for all clinically significant unbalanced chromosome aberrations.
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Objectives: This perspective study aims to investigate the values of placenta volume and the placental volume/Crown-rump length quotient (PQ) on predicting fetal homozygousα 0 -thalassemia (Hb-Bart's disease) by three-dimensional (3D) sonography in first trimester. Methods: From September 2015 to December 2016, two dimensional (2D) ultrasound and 3D ultrasound sonography were performed on singleton pregnancies at risk of α0-thalassemia and normal controls at 7-13+6 weeks of gestation. Affected pregnancies were further confirmed by DNA analysis. Placental volume was measured on 3D ultrasound by a virtual organ computer-aided analysis (VOACL) technique. The interclass correlation coefficient (ICC) was used to analyse the inter-and intraobserver reliability of the 3D ultrasound measurements of 40 fetuses. PQ of the affected pregnancies was compared with that of normal fetuses. Results: Of the 577 fetuses studied, 258 were at risk of a 0 -Thalassemia and 319 were normal controls. 56 (9.71%) fetuses were affected by α 0 -thalassemia. α 0 -thalassemia fetuses all came from the at-risk group while the others were normal. The inter-and intraobserver variability for placental volume by 3D ultrasound measurement was small (inter-and intraclass correlation coefficient were 0.947 and 0.994 respectively). PQ of homozygous α 0 -thalassemia pregnancies showed significant increase compared with that in unaffected group (1.25 ±0.08 vs. 0.94 ± 0.01, P<0.001). PQ ≥ 1.22 was a practical predictor to fetuses with homozygous α 0 -thalassemia with a sensitivity of 53.6%, specificity of 82.7% and an AUC of 0.67 (p < 0.001). Conclusions: Placental volume by 3D ultrasound could be an applicable factor in the first-trimester prediction of fetal homozygous α 0 -thalassemia. Thus may have clinical significance and become a non-invasive technique for early prediction of α 0 -thalassemia.
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Objectives: Use of invasive prenatal diagnosis (IPD) in hepatitis B surface antigen (HBsAg)-positive women carries a potential risk of vertical transmission especially when the viral load is high. The objective of the present study is to investigate HBsAg-positive women's uptake of invasive prenatal diagnosis (IPD) after a positive conventional aneuploidy screening. We hypothesis that more HBSAg-positive than-negative women would choose cell free DNA (cfDNA) testing to avoid IPD and its potential risk of vertical transmission.
